• Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)
  • Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily Jakafi
  • Jakafi XR will be available for pharmacy orders by May 8

Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy.